Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma

Phase 1

Completed

Conditions: Indolent Plasma Cell Myeloma
Plasma Cell Myeloma
Smoldering Plasma Cell Myeloma

Interventions: Biological: Anakinra
Drug: Dexamethasone
Other: Laboratory Biomarker Analysis
Other: Placebo
Drug: Lenalidomide

First Posted Date: 2015-07-09

Last Posted Date: 2020-03-25

Lead Sponsor: Mayo Clinic

Target Recruit Count: 14

Registration Number: NCT02492750

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Procedure: NKAE cells infusion
Drug: Lenalidomide
Drug: Bortezomib

First Posted Date: 2015-06-25

Last Posted Date: 2021-08-20

Lead Sponsor: Joaquín Martínez López, MD, PhD

Target Recruit Count: 5

Registration Number: NCT02481934

Locations: 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain

Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT

Phase 2

Completed

Conditions: Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic
Leukemia, Myeloid, Acute

Interventions: Drug: Lenalidomide
Drug: Azacitidine
Biological: Donor Lymphocyte Infusions

First Posted Date: 2015-06-16

Last Posted Date: 2020-05-28

Lead Sponsor: Heinrich-Heine University, Duesseldorf

Target Recruit Count: 50

Registration Number: NCT02472691

Locations: 🇩🇪
University Hospital Duesseldorf, Dept. of Hematology, Oncology and Clinical Immunology, Duesseldorf, NRW, Germany

Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Adriamycin
Drug: Dexamethasone

First Posted Date: 2015-06-15

Last Posted Date: 2016-10-17

Lead Sponsor: Meletios A. Dimopoulos

Target Recruit Count: 45

Registration Number: NCT02471820

Locations: 🇬🇷
General Hospital of Athens "G. Gennimatas", Athens, Attica, Greece
🇬🇷
University General Hospital of Patras, Patra, Greece
🇬🇷
Theageneio Anticancer Hospital of Thessaloniki, Thessaloniki, Greece

and more 1 locations

A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Relapsed/Refractory Mantle Cell Lymphoma

Interventions: Drug: Lenalidomide
Drug: Ibrutinib
Drug: Rituximab

First Posted Date: 2015-06-02

Last Posted Date: 2020-04-24

Lead Sponsor: Lund University Hospital

Target Recruit Count: 50

Registration Number: NCT02460276

Locations: 🇸🇪
Lund University Hospital, Lund, Sweden
🇸🇪
Uppsala Akademiska Hospital, Uppsala, Sweden
🇩🇰
Rigshospitalet, Copenhagen, Denmark

and more 2 locations

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Recurrent Grade 3a Follicular Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 1 Follicular Lymphoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Drug: Lenalidomide
Biological: Rituximab

First Posted Date: 2015-05-18

Last Posted Date: 2024-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 53

Registration Number: NCT02446457

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Lenalidomide
Drug: Ibrutinib
Drug: Rituximab

First Posted Date: 2015-05-18

Last Posted Date: 2024-02-22

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 27

Registration Number: NCT02446236

Locations: 🇺🇸
The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Lenalidomide
Drug: Dexamethasone
Procedure: Stem Cell Mobilization
Procedure: Autologous Stem Cell Transplant

First Posted Date: 2015-05-12

Last Posted Date: 2024-10-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 46

Registration Number: NCT02441686

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Virginia Piper Cancer Institute, Coon Rapids, Minnesota, United States
🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States

and more 5 locations

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Drug: Lenalidomide
Drug: Daratumumab
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2015-04-30

Last Posted Date: 2021-04-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 85

Registration Number: NCT02431208

Locations: 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸
Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States
🇺🇸
Emory Univ Winship Cancer Inst, Atlanta, Georgia, United States

and more 28 locations

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Hematopoietic Cell Transplantation Recipient
Plasma Cell Myeloma

Interventions: Biological: Elotuzumab
Drug: Lenalidomide
Other: Questionnaire Administration

First Posted Date: 2015-04-20

Last Posted Date: 2024-08-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 113

Registration Number: NCT02420860

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy